The University of Michigan Comprehensive Cancer Center (UWCCC) requests renewal of its core grant in support of senior leadership, programs and shared core facilities. A core grant to support the UMCCC was initially awarded by NCI in 1988 and renewed for five years in 1991 and 1995. The Cancer Center received comprehensive designation in 1991. The Center provides an organizational framework to promote inter- disciplinary research through the development of defined clinical, basic and prevention programs in cancer research, and the development and support of shared resources. The Cancer Center has experienced considerable growth over the current grant period with a 76% increase in NCI funding and a doubling of patient accruals to clinical therapeutic trials. In 1997 the Center moved to a new $88 million facility which houses the Center's outpatient clinics and four and one half floors of research laboratories. The Cancer Center's four basic research programs are: Cancer Genetics/Virology, Cancer Cell Biology, Tumor Immunology and, Experimental Therapeutics. The eight clinical research programs investigating the biology and therapeutics of disease sites are: Cancer Genetics/Virology, Cancer Cell Biology, Tumor Immunology, and Experimental Therapeutics. The eight clinical research programs investigating the biology and therapeutics of disease sites are: Breast, Prostrate, Leukemia/Lymphoma, GI, Cutaneous, Childhood Cancers, Head & Neck, and Connective Tissue. The two prevention programs are Biomedical and Socio-Behavioral. Support is requested for a total of 13 shared core facilities: 11 9ongoing in Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA and Protein Analysis, Morphology Flow Cytometry, Experimental Radiation, Animal Facility, Transgenic Mouse and Vector cores, as well as two new cores in DNA Array Analysis and Immune Monitoring. The Cancer Center senior leadership is composed of the director and five associate directors. Funds are also requested for Development, Planning and Evaluation, and Administration to support Center goals. Over the past 10 years the University and Medical Center have made substantial commitments to the Cancer Center, totaling over $130 million. The UMCCC members receive nearly $66 million in research funding, including over $20 million in annual direct NCI support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-17
Application #
6768828
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1988-09-30
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
17
Fiscal Year
2004
Total Cost
$5,184,039
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications